How Long a GLP-1 Stays in Your Body After the Last Dose
A GLP-1 leaves your system over weeks, not days. The FDA prescribing information for Wegovy gives semaglutide an elimination half-life of approximately 1 week and states that semaglutide will be present in the circulation for about 5 to 7 weeks after the final 2.4 mg dose. Tirzepatide clears somewhat faster, though not fast: the Zepbound prescribing information puts its elimination half-life at approximately 5 to 6 days in patients with overweight or obesity.
Which is why the week after your last injection usually feels like any other week. People read that as proof they never needed the medication. It is not. You are simply still medicated, at a falling dose, by the injection you already took. The clearest signal of how seriously the labels treat this long tail comes from the pregnancy guidance: Wegovy's prescribing information tells patients to discontinue at least 2 months before a planned pregnancy specifically because of semaglutide's long half-life. Zepbound's label instead directs patients to discontinue when a pregnancy is recognized.
If you are still in the ramp-up phase rather than thinking about the exit, our guide to your first month on a GLP-1 covers the other end of the same schedule.
Appetite and Food Noise Come Back First
Appetite returning is the first thing most people notice after stopping a GLP-1, and it tends to arrive before the scale moves. Joshua Neal, M.D., an obesity medicine physician and chief of the Wellness and Human Performance service at MUSC Health, described it in the Medical University of South Carolina's own reporting on coming off these drugs: "That food noise does come back if you come off the medicine."
Patrick O'Neil, Ph.D., director of the MUSC Weight Management Center, describes what the body does next: "The body has a number of tricks up its sleeve to try to regain that weight," including sharper hunger and more intense cravings. O'Neil also points out that losing a significant amount of weight slows your metabolic rate, so the appetite that returns is meeting a body that now burns less than it used to. Two forces, one direction.
In practical terms: portions that felt like plenty at month six start feeling like a snack, and the early fullness that made restaurant meals easy simply stops showing up. The gastrointestinal side effects go the other way and generally fade, which is the one genuinely pleasant part of stopping. Our GLP-1 side effects guide covers that side of the ledger.
What the Two Withdrawal Trials Measured
Two randomized trials have followed what happens when a GLP-1 is deliberately withdrawn, and both found substantial regain. The STEP 1 extension tracked semaglutide, SURMOUNT-4 tracked tirzepatide, and they used different designs, so read the table as two separate experiments rather than a head-to-head comparison.
| Trial | Medication | Design | What happened after withdrawal |
|---|---|---|---|
| STEP 1 extension Diabetes, Obesity and Metabolism, 2022 |
Semaglutide 2.4 mg weekly | 68 weeks of treatment plus lifestyle intervention, then 52 weeks off treatment, 327 participants in the extension analyses | Mean weight loss of 17.3 percent at week 68. Participants regained 11.6 percentage points by week 120, leaving a net 5.6 percent below starting weight. The authors describe this as regaining two-thirds of the prior weight loss. |
| SURMOUNT-4 JAMA, 2023 |
Tirzepatide 10 mg or 15 mg weekly | 36-week open-label lead-in, then 670 participants randomized to continue tirzepatide or switch to placebo for 52 weeks | Mean weight reduction of 20.9 percent during the lead-in. From week 36 to week 88, the continued-tirzepatide group lost a further 5.5 percent while the placebo group gained a mean 14.0 percent. |
Figures are as reported in the published trial results. Trial averages describe groups, not individuals, and your own course will differ.
Notice what the STEP 1 numbers also show: a year after stopping, those participants were still 5.6 percent lighter than when they began. That is not nothing. But the honest framing is the one Dr. Neal used at MUSC: "Most people will regain weight. It is a mix of behavior and biology, but I would say it leans heavily toward biology." Treating regain as a personal failure gets the mechanism backwards. For how the two molecules differ while you are still on them, see our semaglutide vs tirzepatide comparison.
Weight Is Not the Only Thing That Drifts Back
The health markers that improved on a GLP-1 tend to move back toward baseline after withdrawal, alongside the weight. The STEP 1 extension reported that the cardiometabolic improvements seen from week 0 to week 68 with semaglutide reverted toward baseline at week 120 for most variables, and its authors concluded that ongoing treatment is required to maintain the improvements in weight and health.
That single sentence is the reason obesity medicine increasingly treats these drugs as chronic therapy rather than a course of treatment you graduate from. It also changes the arithmetic of stopping for cost reasons, which is one of the most common triggers for stopping in the first place. If price or coverage is the pressure, work through the GLP-1 cost guide and the insurance coverage guide before you decide, because a lower-cost route may exist that you have not been offered.
Does Tapering or Microdosing Make Stopping Easier?
There is no published evidence that tapering a GLP-1 prevents weight regain, and it is worth being clear about that. The FDA prescribing information for Wegovy and Zepbound sets out a detailed dose-escalation schedule for starting treatment, but neither label contains a taper schedule for stopping. Asked about lowering to a maintenance microdose, Dr. Neal of MUSC Health said flatly: "I have not seen any data to support microdosing."
Plenty of clinics sell taper protocols anyway, and a gentler landing may well feel better week to week. Feeling better is a reasonable thing to want. Just do not buy a taper on the belief that it has been shown to hold the weight off, because as of now it has not been. What your prescriber decides about the months after your last dose matters far more than the shape of your final few injections.
One more caution: stopping a GLP-1 prescribed for type 2 diabetes is a different decision from stopping one prescribed for weight management, because blood glucose control is at stake. That conversation belongs with the clinician managing your diabetes, not a guide like this one.
Settle These Questions Before Your Last Injection
Stopping a GLP-1 goes better when it is a planned medical decision rather than a prescription that quietly runs out. Talk with your prescriber before your last dose, and bring the specifics below to that appointment.
- Why you are stopping: cost, side effects, coverage loss, pregnancy plans, or reaching a goal. Each one points to a different plan.
- Whether a lower dose, a different medication, or a coverage appeal is an option you have not tried yet.
- What happens to any condition the medication was also helping, including blood pressure, blood glucose, and lipids.
- A follow-up date. Regain in the trials unfolded over a year, so a check-in at three and six months is more useful than an open-ended goodbye.
- What restarting would involve if you decide to, including whether you would need to re-escalate from the starting dose.
- If pregnancy is the reason, the exact timing your label requires. Wegovy's says at least 2 months before a planned pregnancy.
If your prescription came through a telehealth service, check whether your plan includes clinician follow-up after you stop or only while you are actively paying for medication. Our comparison of online GLP-1 programs flags which ones include ongoing clinician contact rather than a one-time consult.
Frequently Asked Questions
Appetite returns as the medication clears, and in the published withdrawal trials most of the lost weight came back. In the STEP 1 trial extension, published in Diabetes, Obesity and Metabolism in 2022, participants who stopped semaglutide 2.4 mg regained about two-thirds of their prior weight loss within one year, and most of the cardiometabolic improvements they had gained reverted toward baseline. In SURMOUNT-4, published in JAMA, participants switched to placebo after 36 weeks of tirzepatide gained a mean 14.0 percent of body weight over the following year, while those who stayed on tirzepatide lost a further 5.5 percent. Individual results vary, and stopping is a decision to make with your prescriber.
Weeks, not days. The FDA prescribing information for Wegovy gives semaglutide an elimination half-life of approximately 1 week and states that semaglutide will be present in the circulation for about 5 to 7 weeks after the last 2.4 mg dose. The Zepbound prescribing information puts the elimination half-life of tirzepatide at approximately 5 to 6 days in patients with overweight or obesity. That slow clearance is why the first week after a missed or final injection often feels completely normal.
Not necessarily all of it, but plan on regaining a large share. In the STEP 1 extension, semaglutide participants had lost a mean 17.3 percent of body weight at week 68 and were still 5.6 percent below their starting weight a full year after stopping, having regained 11.6 percentage points. That is a meaningful amount kept and a large amount returned. Joshua Neal, M.D., an obesity medicine physician at MUSC Health, has said that most people will regain weight and that the cause leans heavily toward biology rather than behavior.
There is no published evidence that tapering prevents weight regain. The FDA prescribing information for Wegovy and Zepbound sets out a dose-escalation schedule for starting treatment, but neither label contains a taper schedule for stopping. Joshua Neal, M.D., of MUSC Health has stated that he has not seen any data to support microdosing. Some clinics sell structured taper protocols anyway. Ask your prescriber what the plan is for the months after your last dose, because that plan matters more than the shape of the final few injections.
Thinking About Stopping? Have the Conversation First
Whether to continue, pause, or stop a GLP-1 is a medical decision, and the trial data says the months after your last dose are the ones that matter. Licensed online programs include clinicians who can review your history, look at the reason you want to stop, and tell you whether a different dose or medication is worth trying first.
Prescription required. Medical screening and clinician review required. Not all patients will qualify. Affiliate disclosure: this site may earn a referral fee from programs listed.
Compare Online GLP-1 ProgramsSources
The following sources were used for the pharmacokinetics, trial results, and clinician commentary referenced on this page. Always verify against the most current version of each document.
- Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism, 2022: week 68 and week 120 weight outcomes and cardiometabolic reversion.
- Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA, 2023: 36-week lead-in reduction and week 36 to 88 weight change with continued tirzepatide versus placebo.
- Wegovy (semaglutide) US Prescribing Information, Novo Nordisk: elimination half-life, duration in circulation after the last dose, and pre-pregnancy discontinuation guidance.
- Zepbound (tirzepatide) US Prescribing Information, Eli Lilly: elimination half-life in patients with overweight or obesity, time to steady state, and discontinuation on recognition of pregnancy.
- Medical University of South Carolina (MUSC) Content Hub: "Life after Ozempic: What happens when you stop a GLP-1?" Comments from Joshua Neal, M.D., and Patrick O'Neil, Ph.D.